MedTrace Logo

Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia

NCT00664677 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2016-02-23

No results posted yet for this study

Summary

This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous infusion three times a week in patients with leukemia.

Conditions

  • Leukemias
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphocytic Leukemia (ALL)
  • Adult T Cell Leukemia (ATL)
  • Chronic Myeloid Leukemia (CML-BP)
  • Chronic Lymphocytic Leukemia (CLL)
  • Myelodysplastic Syndrome (MDS)
  • Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG

Terameprocol (EM-1421)

Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.

Sponsors & Collaborators

  • Erimos Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Neil Frazer, MB, ChB · Erimos Pharmaceutical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-03-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664677 on ClinicalTrials.gov